In a strategic move to address growing demand for flexible softgel manufacturing, Lonza has unveiled an upgraded hollow capsule production line designed to increase throughput while maintaining pharmaceutical-grade quality. The new system - deployed at Lonza's manufacturing site in Visp, Switzerland - combines automated encapsulation technologies with enhanced process analytical tools to reduce variability and accelerate batch release for nutraceutical and pharmaceutical customers.
Lonza's customers have recently faced a dual challenge: rising demand for oral softgels and more complex regulatory expectations for uniformity and traceability. The company's response centered on modernizing its hollow capsule production line to achieve both higher output and superior process control. The upgraded system integrates precision dosing, real-time viscosity monitoring, and closed-loop environmental controls to maintain gel shell consistency throughout long production runs.
According to Lonza plant leadership, the new line delivers a 25–35% increase in effective throughput for typical hollow capsule SKUs, primarily by reducing downtime associated with shell feed stabilization and cleaning cycles. The line's automated CIP (clean-in-place) routines and quick-change tooling also shorten product changeover times, enabling faster product transitions for contract manufacturing customers with diverse SKU portfolios.
Quality assurance is a major focus. Inline inspection modules employing machine-vision cameras and laser micrometry inspect shell thickness and sphericity at high speed, flagging deviations for immediate correction. Data captured during production are fed into Lonza's electronic batch records and analytics platform, providing customers with transparent quality documentation and trending analyses. This capability is particularly valuable for clinical-phase customers who require stringent batch documentation and for post-approval commercial customers managing supply chains across multiple sites.
Sustainability features were also incorporated. The system reduces solvent use during cleaning cycles and optimizes energy consumption via heat recovery from exhaust streams. Lonza reports initial metrics showing lower water and energy use per 1 million capsules produced compared with legacy lines, aligning with the company's broader sustainability targets.
Customers piloting the line include both established nutraceutical brands seeking faster time-to-market for new softgel formulations and emerging biopharma companies developing lipid-based drug-delivery capsules. Early adopters have highlighted the system's flexibility to handle a range of fill viscosities and shell formulations, including fast-release and enteric-coated shells.
Industry analysts note that investments like Lonza's reflect a wider trend toward modular, digitally enabled encapsulation lines across contract manufacturers. As formulations diversify - from omega-3 concentrates to complex lipid nanoparticles - manufacturers that can scale production while preserving quality and traceability will gain competitive advantage.
Lonza's investment underscores the continuing importance of process modernization in softgel manufacturing. By combining automation, inline analytics, and sustainability improvements, the company aims to help customers accelerate product launches while meeting rising regulatory and environmental expectations.
Image suggestion: Photograph of Lonza's Visp manufacturing building or a close-up of a robotic encapsulation line.
Where to source: Lonza official press release pages (Lonza website) or licensed industrial photography from Shutterstock/Getty Images.
